By: Nathalie M. Johnson, MD – Legacy Health Partners
Conference: ASBrS
Dr. Nathalie M. Johnson, MD, a breast cancer specialist with Legacy Health Partners, delves into the evolving role of circulating tumor DNA (ctDNA) in the management of breast cancer. As the field of oncology continues to advance, Dr. Johnson emphasizes the importance of adopting ctDNA testing more widely to improve patient outcomes, particularly for those with high-risk breast cancer types.
The Role of ctDNA in Breast Cancer Management
Dr. Johnson begins by highlighting how ctDNA is becoming a crucial tool in her practice. Although there aren’t standardized guidelines for its use just yet, she stresses that ctDNA testing can be particularly beneficial for certain groups of patients, such as those with triple-negative disease or HER2-positive disease.
“I am using ctDNA in my practice, and I think that we all need to start using it a little bit more widely,” says Dr. Johnson.
The Impact on High-Risk Patient Groups
One of the key points Dr. Johnson discusses is the use of ctDNA in patients with triple-negative breast cancer who have residual disease after neoadjuvant treatment. These patients are at a higher risk, and current treatment options may not be sufficient. However, monitoring these patients with ctDNA offers new possibilities.
“If we’re monitoring them with ctDNA, we do have other options,” she explains. “It appears that if we start treatment earlier, we can prolong their life and give them a better quality of life.”
Similarly, Dr. Johnson highlights the impact of ctDNA on HER2-positive breast cancer patients. With advancements in treatment, the lifespan of patients with recurring HER2-positive disease has significantly increased, underscoring the value of early detection and intervention.
Moving Towards Routine Use of ctDNA
Dr. Johnson believes that ctDNA should be considered more routinely, especially for high-risk patient groups. Early detection through ctDNA could lead to earlier interventions, potentially resulting in better outcomes and improved quality of life for patients.
As the medical community continues to explore the potential of ctDNA, it is clear that this technology could revolutionize the way breast cancer is managed, offering hope for patients and clinicians alike.
Conclusion
The integration of ctDNA into clinical practice represents a significant advancement in breast cancer treatment. Dr. Nathalie M. Johnson’s insights provide a compelling case for the broader adoption of ctDNA testing, particularly for those patients who stand to benefit the most from early detection and personalized treatment strategies.
Related Links on OncologyTube:
More Related Links:
American Cancer Society: Understanding Breast Cancer DNA Testing
- Link: American Cancer Society – DNA Testing in Breast Cancer
- Description: This page provides detailed information about the role of DNA testing in breast cancer, including the use of circulating tumor DNA (ctDNA) for early detection and treatment monitoring.
National Cancer Institute: ctDNA and Its Role in Cancer Treatment
- Link: National Cancer Institute – Circulating Tumor DNA
- Description: Explore the National Cancer Institute’s comprehensive overview of circulating tumor DNA (ctDNA), how it works, and its potential benefits in personalizing cancer treatment, particularly for high-risk breast cancer patients.
Related Links: